Pharmacometabonomics in humans: A new tool for personalized medicine

Pharmacogenomics

Volumn 16, Issue 7, 2015, Pages 737-754

  Everett, Jeremy R ^a  

^a UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

metabolomics; metabonomics; NMR spectroscopy; personalized medicine; pharmacometabolomics; pharmacometabonomics; precision medicine

Indexed keywords

ACETYLSALICYLIC ACID; CAPECITABINE; CITALOPRAM; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESCITALOPRAM; FLUOROURACIL; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; MIDAZOLAM; PARA CRESOL; PARACETAMOL; PARACETAMOL GLUCURONIDE; PARACETAMOL SULFATE; PLACEBO; RIFAMPICIN; SERTRALINE; SIMVASTATIN; TACROLIMUS; TRIMETHYLSILYL DERIVATIVE; TRIMETHYLSILYLPROPIONATE; UNCLASSIFIED DRUG;

BODY FLUID; BREAST CANCER; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SULFATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR DEPRESSION; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENOMICS; PHARMACOMETABONOMICS; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL ANALYSIS; URINALYSIS; ANIMAL; PHARMACOGENETICS; PROCEDURES; TRENDS;

ANIMALS; HUMANS; METABOLOMICS; PHARMACOGENETICS; PRECISION MEDICINE;

EID: 84930686671     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.20     Document Type: Review

References (61)

1. Jorgensen JT. A challenging drug development process in the era of personalized medicine. Drug Discov. Today 16(19-20), 891-897 (2011).
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients-a meta-analysis of prospective studies. JAMA 279(15), 1200-1205 (1998).
3. Miguel A, Azevedo LF, Araujo M, Pereira AC. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol. Drug Safety 21(11), 1139-1154 (2012).
4. Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J. Pharmacol. Pharmacother. 4(Suppl. 1), S73-77 (2013).
5. Lee JW, Aminkeng F, Bhavsar AP et al. The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin. Genet. 86(1), 21-28 (2014).
6. Pirmohamed M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu. Rev. Genom. Hum. Genet. 15, 349-370 (2014).
7. Pokorska-Bocci A, Stewart A, Sagoo GS, Hall A, Kroese M, Burton H. 'Personalized medicine': what's in a name Personal. Med. 11(2), 197-210 (2014).
8. Joseph PG, Pare G, Ross S, Roberts R, Anand SS. Pharmacogenetics in cardiovascular disease: the challenge of moving from promise to realization concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009. Clin. Cardiol. 37(1), 48-56 (2014).
9. Maruthur NM, Gribble MO, Bennett WL et al. The pharmacogenetics of Type 2 diabetes: a systematic review. Diabetes Care 37(3), 876-886 (2014).
10. Perlis RH. Pharmacogenomic testing and personalized treatment of depression. Clin. Chem. 60(1), 53-59 (2014).
11. Carr DF, Alfirevic A, Pirmohamed M. Pharmacogenomics: current state-of-the-art. Genes 5(2), 430-443 (2014).
12. Lindon J, Nicholson J, Holmes E, Everett J. Metabonomics: metabolic processes studied by NMR spectroscopy of biofluids. Concepts Magn. Reson. 12(5), 289-320 (2000).
13. Lindon J, Nicholson J, Everett J. NMR spectroscopy of biofluids. In: Annual Reports on NMR Spectroscopy, Volume 38. Academic Press, London, UK 1-88 (1999).
14. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Mol. Biol. 48(1-2), 155-171 (2002).
15. Lindon JC, Nicholson JK, Holmes E. The handbook of metabonomics and metabolomics Elsevier, Amsterdam, Oxford (2007).
16. Clayton T, Lindon J, Cloarec O et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440(7087), 1073-1077 (2006).
17. Kaddurah-Daouk R, Boyle SH, Matson W et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl. Psychiatry 1, 1-7 (2011).
18. Kaddurah-Daouk R, Baillie RA, Zhu H et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS ONE 6(10), e25482 (2011).
19. Wishart DS. Characterization of biopharmaceuticals by NMR spectroscopy. Trends Anal. Chem. 48, 96-111 (2013).
20. Sumner LW, Amberg A, Barrett D et al. Proposed minimum reporting standards for chemical analysis. Metabolomics 3(3), 211-221 (2007).
21. Dunn WB, Erban A, Weber RJM et al. Mass appeal: metabolite identification in mass spectrometry-focused untargeted metabolomics. Metabolomics 9(1), S44-S66 (2013).
22. Creek DJ, Dunn WB, Fiehn O et al. Metabolite identification: are you sure And how do your peers gauge your confidence Metabolomics 10(3), 350-353 (2014).
23. Everett JR. A new paradigm for known metabolite identification in metabonomics/metabolomics: metabolite identification efficiency. Computational and Structural Biotechnology Journal 13, 131-144 (2015).
24. Burton K, Everett J, Newman M, Pullen F, Richards D, Swanson A. On-line liquid chromatography coupled with high field NMR and mass spectrometry (LC-NMR-MS): a new technique for drug metabolite structure elucidation. J. Pharm. Biomed. Anal. 15(12), 1903-1912 (1997).
25. Claridge T. High-Resolution NMR Techniques in Organic Chemistry Elsevier, Oxford, UK (2009).
26. Wishart DS, Jewison T, Guo AC et al. HMDB 3.0-The Human Metabolome Database in 2013. Nucleic Acids Res. 41(D1), D801-D807 (2013).
27. Craig A, Cloarec O, Holmes E, Nicholson JK, Lindon JC. Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal. Chem. 78(7), 2262-2267 (2006).
28. Dona AC, Jimenez B, Schaefer H et al. Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Anal. Chem. 86(19), 9887-9894 (2014).
29. Emwas A-HM, Salek RM, Griffin JL, Merzaban J. NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations. Metabolomics. 9(5), 1048-1072 (2013).
30. Lindon JC, Nicholson JK. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu. Rev. Anal. Chem. 1, 45-69 (2008).
31. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl Acad. Sci. USA 106(34), 14728-14733 (2009).
32. Wilson ID. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc. Natl Acad. Sci. USA 106(34) 14187-14188 (2009).
33. Everett JR, Loo RL, Pullen FS. Pharmacometabonomics and personalized medicine. Ann. Clin. Biochem. 50, 523-545 (2013).
34. Nicholson JK, Wilson ID, Lindon JC. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 12(1), 103-111 (2011).
35. Fanos V, Barberini L, Antonucci R, Atzori L. Pharma-metabolomics in neonatology: is it a dream or a fact Curr. Pharm. Des. 18(21), 2996-3006 (2012).
36. Antonucci R, Pilloni MD, Atzori L, Fanos V. Pharmaceutical research and metabolomics in the newborn. J. Matern. Fetal Neonatal Med. 25, 22-26 (2012).
37. Phapale PB, Kim SD, Lee HW et al. An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus. Clin. Pharmacol. Ther. 87(4), 426-436 (2010).
38. Rahmioglu N, Le Gall G, Heaton J et al. Prediction of variability in CYP3A4 induction using a combined H-1 NMR metabonomics and targeted UPLC-MS approach. J. Proteome Res. 10(6), 2807-2816 (2011).
39. Shin KH, Choi MH, Lim KS, Yu KS, Jang IJ, Cho JY. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clin. Pharmacol. Ther. 94(5), 601-609 (2013).
40. Kaddurah-Daouk R, Baillie RA, Zhu HJ et al. Lipidomic analysis of variation in response to simvastatin in the cholesterol and pharmacogenetics study. Metabolomics 6(2), 191-201 (2010).
41. Trupp M, Zhu H, Wikoff WR et al. Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PLoS ONE 7(7), e38386 (2012).
42. Ji Y, Hebbring S, Zhu H et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin. Pharmacol. Ther. 89(1), 97-104 (2011).
43. Abo R, Hebbring S, Ji Y et al. Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet. Genomics 22(4), 247-253 (2012).
44. Kaddurah-Daouk R, Bogdanov MB, Wikoff WR et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl. Psychiatry 3, e223 (2013).
45. Zhu H, Bogdanov MB, Boyle SH et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder-possible role for methoxyindole pathway. PLoS ONE 8(7), e68283 (2013).
46. Condray R, Dougherty GG, Keshavan MS et al. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int. J. Neuropsychopharmacol. 14(6), 756-767 (2011).
47. Lewis JP, Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Kaddurah-Daouk R, Hankemeier T. Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. Clin. Pharmacol. Ther. 94(5), 570-573 (2013).
48. Ellero-Simatos S, Lewis JP, Georgiades A et al. Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. Pharmacometr. Syst. Pharmacol. 3, e125-e125 (2014).
49. Keun HC, Sidhu J, Pchejetski D et al. Serum molecular signatures of weight change during early breast cancer chemotherapy. Clin. Cancer Res. 15(21), 6716-6723 (2009).
50. Backshall A, Sharma R, Clarke SJ, Keun HC. Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin. Cancer Res. 17(9), 3019-3028 (2011).
51. Winnike JH, Li Z, Wright FA, Macdonald JM, O'Connell TM, Watkins PB. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin. Pharmacol. Ther. 88(1), 45-51 (2010).
52. Wang-Sattler R, Yu Z, Herder C et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol. Syst. Biol. 8, 615 (2012).
53. Kema IP, de Vries EGE, Muskiet FAJ. Clinical chemistry of serotonin and metabolites. J. Chromatogr. B. 747(1-2), 33-48 (2000).
54. Wikoff WR, Frye RF, Zhu H et al. Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS ONE 8(3), e57639-e57639 (2013).
55. Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A et al. Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. Clin. Pharmacol. Ther. 94(4), 525-532 (2013).
56. Nicholson JK, Everett JR, Lindon JC. Longitudinal pharmacometabonomics for predicting patient responses to therapy: drug metabolism, toxicity and efficacy. Expert Opin. Drug Metab. Toxicol. 8(2), 135-139 (2012).
57. Suhre K, Shin S-Y, Petersen A-K et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477(7362), U54-U60 (2011).
58. Suhre K, Wallaschofski H, Raffler J et al. A genome-wide association study of metabolic traits in human urine. Nat. Genet. 43(6), U565-U597 (2011).
59. Kettunen J, Tukiainen T, Sarin A-P et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat. Genet. 44(3), U269-U265 (2012).
60. Shin S-Y, Fauman EB, Petersen A-K et al. An atlas of genetic influences on human blood metabolites. Nat. Genet. 46(6), 543-550 (2014).
61. Rueedi R, Ledda M, Nicholls AW et al. Genome-wide association study of metabolic traits reveals novel gene-metabolite-disease links. PLoS Genet. 10(2), e1004132-e1004132 (2014).